<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47093/2218-7332.2021.12.4.39-50</article-id><article-id custom-type="elpub" pub-id-type="custom">sechenov-415</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NEUROSURGERY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕЙРОХИРУРГИЯ</subject></subj-group></article-categories><title-group><article-title>Cytokine profile in the peripheral blood and the brain in patients with focal drug-resistant epilepsy</article-title><trans-title-group xml:lang="ru"><trans-title>Исследование цитокинового профиля в периферической крови и головном мозге у пациентов с фокальной фармакорезистентной эпилепсией</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9721-3827</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ситовская</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sitovskaia</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-патологоанатом, научный сотрудник научно-исследовательскойлаборатории патоморфологии нервной системы; ассистент кафедры патологической анатомии </p><p>Tel.: +7 (981) 761-31-97 </p><p>ул. Маяковского, д. 12, Санкт-Петербург, 191014, Россия</p><p>ул. Литовская, д. 2, Санкт-Петербург, 194100, Россия</p></bio><bio xml:lang="en"><p> pathologist, researcher, Research Laboratory of Nervous System Pathomorphology; Assistant Professor, Department of Pathology </p><p> Tel.: +7 (981) 761-31-97 </p><p>12, Mayakovskogo str., Saint-Petersburg, 191014, Russia</p><p>2, Litovskaya str., Saint-Petersburg, 194100, Russia</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7810-0832</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литовченко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Litovchenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант лаборатории сравнительной биохимии и клеточных функций </p><p>пр. Тореза, д. 44, Санкт-Петербург, 194223, Россия</p></bio><bio xml:lang="en"><p>post-graduate student, Laboratory of Comparative Biochemistry and Cellular Functions</p><p>44, Toreza av., Saint-Petersburg, 194223, Russia</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9763-504X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бажанова</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Bazhanova</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, ведущий научный сотрудник лаборатории сравнительной биохимии и клеточных функций; заведующая лабораторией морфологии и электронной микроскопии; старший научный сотрудник кафедры  биохимии </p><p>пр. Тореза, д. 44, Санкт-Петербург, 194223, Россия</p><p>ул. Бехтерева, д. 1, Санкт-Петербург, 192019, Россия</p><p>ул. Татищева, д. 20а, Астрахань, 414000, Россия</p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Leading Researcher, Laboratory of Comparative Biochemistry and Cellular Functions; Head of the Laboratory of Morphology and Electron Microscopy; Senior Researcher,  Department of Biochemistry</p><p>44, Toreza av., Saint-Petersburg, 194223, Russia</p><p>1, Bechtereva str., Saint-Petersburg, 192019, Russia </p><p> 20a, Tatischeva str., Astrakhan, 414000, Russia </p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7008-6389</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скитева</surname><given-names>Е. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Skiteva</surname><given-names>E. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> младший научный сотрудник научно-исследовательской лаборатории патоморфологии нервной системы </p><p>ул. Маяковского, д. 12, Санкт-Петербург, 191014, Россия</p></bio><bio xml:lang="en"><p> junior researcher, Research Laboratory of Nervous System Pathomorphology</p><p> 12, Mayakovskogo str., Saint-Petersburg, 191014, Russia </p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6206-2133</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Забродская</surname><given-names>Ю. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Zabrodskaia</surname><given-names>Yu. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, заведующая научно-исследовательской лабораторией патоморфологии нервной системы; ведущий научный сотрудник лаборатории морфологии и электронной микроскопии; доцент кафедры патологической анатомии </p><p>ул. Маяковского, д. 12, Санкт-Петербург, 191014, Россия</p><p>ул. Бехтерева, д. 1, Санкт-Петербург, 192019, Россия</p><p>ул. Академика Лебедева, д. 6, Санкт-Петербург, 194044, Россия</p></bio><bio xml:lang="en"><p> Dr. of Sci. (Med.), Head of the Research Laboratory of Nervous System Pathomorphology; Leading Researcher, Laboratory of Morphology and Electron Microscopy; Associate Professor, Department of Pathology</p><p> 12, Mayakovskogo str., Saint-Petersburg, 191014, Russia </p><p>1, Bechtereva str., Saint-Petersburg, 192019, Russia</p><p>6, Academician Lebedev str., Saint-Petersburg, 194044, Russia</p></bio><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский научно-исследовательский нейрохирургический институт имени профессора А.Л. Поленова – филиал ФГБУ «Национальный  медицинский исследовательский центр имени В.А. Алмазова» Минздрава России;&#13;
ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Polenov Neurosurgical Institute – Branch of Almazov National Medical Research Centre;&#13;
Saint Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУН «Институт эволюционной физиологии и биохимии им. И.М. Сеченова РАН»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУН «Институт эволюционной физиологии и биохимии им. И.М. Сеченова РАН»;&#13;
ГБУ «Научно-клинический центр токсикологии имени академика С.Н. Голикова ФМБА России»;&#13;
ФГБОУ ВО «Астраханский государственный университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences;&#13;
Golikov Research Clinical Center of Toxicology under the Federal&#13;
Medical Biological Agency;&#13;
Astrakhan State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Российский научно-исследовательский нейрохирургический институт имени профессора А.Л. Поленова – филиал ФГБУ «Национальный  медицинский исследовательский центр имени В.А. Алмазова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Polenov Neurosurgical Institute – Branch of Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Российский научно-исследовательский нейрохирургический институт имени профессора А.Л. Поленова – филиал ФГБУ «Национальный  медицинский исследовательский центр имени В.А. Алмазова» Минздрава России;&#13;
ФГБУ «Научно-клинический центр токсикологии имени академика С.Н. Голикова ФМБА России»;&#13;
ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Polenov Neurosurgical Institute – Branch of Almazov National Medical Research Centre;&#13;
Golikov Research Clinical Center of Toxicology under the Federal Medical Biological Agency;&#13;
S.M. Kirov Military Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2021</year></pub-date><volume>12</volume><issue>4</issue><issue-title>Special Issue "Neurosurgery"</issue-title><fpage>39</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Sitovskaia D.A., Litovchenko A.V., Bazhanova E.D., Skiteva E.N., Zabrodskaia Y.M., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ситовская Д.А., Литовченко А.В., Бажанова Е.Д., Скитева Е.Н., Забродская Ю.М.</copyright-holder><copyright-holder xml:lang="en">Sitovskaia D.A., Litovchenko A.V., Bazhanova E.D., Skiteva E.N., Zabrodskaia Y.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/415">https://www.sechenovmedj.com/jour/article/view/415</self-uri><abstract><p>Aim. To study markers of blood-brain barrier dysfunction (BBB) in patients with pharmacoresistant epilepsy (PhRE) – the amount of VEGF in endotheliocytes of brain capillaries, TNF-α in brain tissue and cytokine profile in blood serum.Materials and methods. The study included 30 patients with PhRE who underwent anterior temporal bloc resection. Histological samples of the brain were examined to assess the amount of VEGF and TNF-α; the concentration of cytokines in the blood serum was determined.Results. In the PhRE group, the densitometric density of cells expressing VEGF and the amount of TNF-α in the epileptogenic focus were higher than in the control groups (p &lt; 0.001; p &lt; 0.05). Compared with the control, the serum concentrations of IL-2 (0.98 ± 0.28 pg/ml vs. 2.80 ± 0.71 pg/ml; p &lt; 0.001), IL-8 (14.04 ± 1.46 pg/ml vs. 26.13 ± 3.80 pg/ml; p &lt; 0.001) and EGF (43.72 ± 5.63 pg/ml vs. 83.62 ± 24.06 pg/ml; p &lt; 0.05) were statistically significantly lower in the PhRE group, and the amount of TNF-α (33.09 ± 1.23 pg/ml vs. 24.85 ± 1.32 pg/ml, p &lt; 0.05), IL-4 (43.73 ± 2.57 pg/ml vs. 32.37 ± 5.80 pg/ml, p &lt; 0.05), IL-5 (43.73 ± 2.57 pg/ml vs. 32.37 ± 5.80 pg/ml; p &lt; 0.05), IL-7 (16.65 ± 3.07 pg/ml vs. 8.13 ± 1.67 pg/ml; p &lt; 0.05), GRO (growth-regulated protein) (3054.0 ± 200.8 pg/ml vs. 1367.0 ± 187.3 pg/ml; p &lt; 0.001), VEGF (316.10 ± 55.28 pg/ml vs. 95.22 ± 15.78 pg/ml; p &lt; 0.01) are statistically significantly higher. There were no significant differences in the concentration of IL-1β, IL-1RA, IL-10 and IFN-γ between the PhRE group and the control.Conclusion. Based on the studied cytokine profile, there is no systemic inflammation in patients with PhRE. The established overexpression of VEGF in the brain and an increase in its concentration in the blood, combined with a decrease in serum EGF concentrations and an increase in GRO, as well as pro-inflammatory factors, indicates damage to the BBB. A high amount of TNF-α in the epileptic focus indicates neuroinflammation, and an increased concentration of this marker can be found in the blood of patients with BBB dysfunction.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Изучить у пациентов с фармакорезистентной эпилепсией (ФРЭ) маркеры дисфункции гематоэнцефалического барьера (ГЭБ) – содержание VEGF в эндотелиоцитах капилляров мозга, TNF-α в ткани мозга и цитокиновый профиль в сыворотке крови.Материалы и методы. В исследование включены 30 пациентов с ФРЭ, которым проведена передняя темпоральная блок-резекция. Исследованы гистологические образцы головного мозга для оценки содержания VEGF и TNF-α; определена концентрация цитокинов в сыворотке крови.Результаты. В группе ФРЭ денситометрическая плотность клеток, экспрессирующих VEGF и содержание TNF-α в эпилептическом очаге, была выше, чем в контрольных группах (p &lt; 0,001; p &lt; 0,05). По сравнению с контролем в сыворотке крови пациентов с ФРЭ концентрация IL-2 (0,98 ± 0,28 против 2,80 ± 0,71 пг/мл; p &lt; 0,001), IL-8 (14,04 ± 1,46 против 26,13 ± 3,80 пг/мл; p &lt; 0,001) и EGF (43,72 ± 5,63 против 83,62 ± 24,06 пг/мл; p &lt; 0,05) была статистически значимо ниже, а содержание TNF-α (33,09 ± 1,23 против 24,85 ± 1,32 пг/мл, p &lt; 0,05), IL-4 (43,73 ± 2,57 против 32,37 ± 5,80 пг/мл, p &lt; 0,05), IL-5 (43,73 ± 2,57 против 32,37 ± 5,80 пг/мл; p &lt; 0,05), IL-7 (16,65 ± 3,07 против 8,13 ± 1,67 пг/мл; p &lt; 0,05), GRO (growth-regulated protein) (3054,0 ± 200,8 против 1367,0 ± 187,3 пг/мл; p &lt; 0,001), VEGF (316,10 ± 55,28 против 95,22 ± 15,78 пг/мл; p &lt; 0,01) статистически значимо выше. Существенных различий по концентрации IL-1β, IL-1RA, IL-10 и IFN-γ между группами ФРЭ и контролем не установлено.Заключение. Исходя из изученного цитокинового профиля можно заключить, что у пациентов с ФРЭ отсутствует системное воспаление. Установленная гиперэкспрессия VEGF в головном мозге и увеличение концентрации его в крови в сочетании со снижением концентраций EGF в сыворотке крови и повышением GRO, а также провоспалительных факторов свидетельствует о повреждении ГЭБ. Высокое содержание TNF-α непосредственно в эпилептическом очаге свидетельствует о нейровоспалении, и в условиях дисфункции ГЭБ можно обнаружить повышенную концентрацию TNF-α в крови пациентов.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>эпилепсия</kwd><kwd>гематоэнцефалический барьер</kwd><kwd>VEGF</kwd><kwd>цитокины</kwd><kwd>нейровоспаление</kwd><kwd>плотные контакты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>epilepsy</kwd><kwd>blood-brain barrier</kwd><kwd>VEGF</kwd><kwd>cytokines</kwd><kwd>neuroinflammation</kwd><kwd>tight junctions</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование цитокинов выполнено в рамках гранта РФФИ № 20-015-00127 и на оборудовании ЦКП ИЭФБ РАН. Иммуногистохимическое исследование проводилось в рамках Госзадания №121031000359-3 «Разработка новых подходов в диагностике медиобазальной фармакорезистентной эпилепсии на основе гистопротеомики эпилептических очагов».</funding-statement><funding-statement xml:lang="en">The study of citokines was carried out within the framework of the RFBR grant № 20-015-00127 and on the equipment of the CCU of the IEFB RAS. Immunohistochemical study was performed within the framework State task No. 121031000359-3 "Development of new approaches in the diagnosis of mediobasal pharmacoresistant epilepsy based on histoproteomics of epileptic foci".</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sheng J., Liu S., Qin H., et al. Drug-Resistant epilepsy and surgery. Curr Neuropharmacol. 2018; 16(1): 17–28. https://doi.org/10.2174/1570159X15666170504123316. PMID: 28474565.</mixed-citation><mixed-citation xml:lang="en">Sheng J., Liu S., Qin H., et al. Drug-Resistant epilepsy and surgery. Curr Neuropharmacol. 2018; 16(1): 17–28. https://doi.org/10.2174/1570159X15666170504123316. PMID: 28474565.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sone D. Making the Invisible Visible: Advanced Neuroimaging Techniques in Focal Epilepsy. Front Neurosci. 2021 Jul 27; 15: 699176. https://doi.org/10.3389/fnins.2021.699176. PMID: 34385902.</mixed-citation><mixed-citation xml:lang="en">Sone D. Making the Invisible Visible: Advanced Neuroimaging Techniques in Focal Epilepsy. Front Neurosci. 2021 Jul 27; 15: 699176. https://doi.org/10.3389/fnins.2021.699176. PMID: 34385902.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Abbott N.J., Friedman A. Overview and introduction: the bloodbrain barrier in health and disease. Epilepsia. 2012 Nov; 53 Suppl 6(0 6): 1–6. https://doi.org/10.1111/j.1528-1167.2012.03696.x. PMID: 23134489.</mixed-citation><mixed-citation xml:lang="en">Abbott N.J., Friedman A. Overview and introduction: the bloodbrain barrier in health and disease. Epilepsia. 2012 Nov; 53 Suppl 6(0 6): 1–6. https://doi.org/10.1111/j.1528-1167.2012.03696.x. PMID: 23134489.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman A., Heinemann U. Role of blood-brain barrier dysfunction in epileptogenesis. In: Noebels J.L., Avoli M., Rogawski M.A., Olsen R.W., Delgado-Escueta A.V., editors. Jasper’s Basic Mechanisms of the epilepsies. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PMID: 22787606.</mixed-citation><mixed-citation xml:lang="en">Friedman A., Heinemann U. Role of blood-brain barrier dysfunction in epileptogenesis. In: Noebels J.L., Avoli M., Rogawski M.A., Olsen R.W., Delgado-Escueta A.V., editors. Jasper’s Basic Mechanisms of the epilepsies. 4th ed. Bethesda (MD): National Center for Biotechnology Information (US); 2012. PMID: 22787606.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Baruah J., Vasudevan A., Köhling R. Vascular Integrity and Signaling Determining Brain Development, Network Excitability, and Epileptogenesis. Front Physiol. 2020 Jan 22;10:1583. https://doi.org/10.3389/fphys.2019.01583. PMID: 32038280.</mixed-citation><mixed-citation xml:lang="en">Baruah J., Vasudevan A., Köhling R. Vascular Integrity and Signaling Determining Brain Development, Network Excitability, and Epileptogenesis. Front Physiol. 2020 Jan 22;10:1583. https://doi.org/10.3389/fphys.2019.01583. PMID: 32038280.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Commins S.P., Borish L., Steinke J.W. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010 Feb; 125(2 Suppl 2): S53–72. https://doi.org/10.1016/j.jaci.2009.07.008. Epub 2009 Nov 24. PMID: 19932918.</mixed-citation><mixed-citation xml:lang="en">Commins S.P., Borish L., Steinke J.W. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010 Feb; 125(2 Suppl 2): S53–72. https://doi.org/10.1016/j.jaci.2009.07.008. Epub 2009 Nov 24. PMID: 19932918.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Geiseler S.J., Morland C. The Janus face of VEGF in stroke. Int J Mol Sci. 2018 May 4; 19(5): 1362. https://doi.org/10.3390/ijms19051362. PMID: 29734653.</mixed-citation><mixed-citation xml:lang="en">Geiseler S.J., Morland C. The Janus face of VEGF in stroke. Int J Mol Sci. 2018 May 4; 19(5): 1362. https://doi.org/10.3390/ijms19051362. PMID: 29734653.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sweeney M.D., Zhao Z., Montagne A., et al. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019 Jan 1; 99(1): 21–78. https://doi.org/10.1152/physrev.00050.2017. PMID: 30280653.</mixed-citation><mixed-citation xml:lang="en">Sweeney M.D., Zhao Z., Montagne A., et al. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019 Jan 1; 99(1): 21–78. https://doi.org/10.1152/physrev.00050.2017. PMID: 30280653.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ureña-Guerrero M.E., Castañeda-Cabral J.L., Rivera-Cervantes MC, et al. Neuroprotective and neurorestorative effects of EPO and VEGF: perspectives for new therapeutic approaches to neurological diseases. Curr Pharm Des. 2020; 26(12): 1263–1276. https://doi.org/10.2174/1381612826666200114104342. PMID:31942853.</mixed-citation><mixed-citation xml:lang="en">Ureña-Guerrero M.E., Castañeda-Cabral J.L., Rivera-Cervantes MC, et al. Neuroprotective and neurorestorative effects of EPO and VEGF: perspectives for new therapeutic approaches to neurological diseases. Curr Pharm Des. 2020; 26(12): 1263–1276. https://doi.org/10.2174/1381612826666200114104342. PMID:31942853.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Castañeda-Cabral J.L., Beas-Zárate C., Rocha-Arrieta L.L., et al. Increased protein expression of VEGF-A, VEGF-B, VEGF-C and their receptors in the temporal neocortex of pharmacoresistant temporal lobe epilepsy patients. J Neuroimmunol. 2019 Mar 15; 328: 68–72. https://doi.org/10.1016/j.jneuroim.2018.12.007. Epub 2018 Dec 21. PMID: 30597392.</mixed-citation><mixed-citation xml:lang="en">Castañeda-Cabral J.L., Beas-Zárate C., Rocha-Arrieta L.L., et al. Increased protein expression of VEGF-A, VEGF-B, VEGF-C and their receptors in the temporal neocortex of pharmacoresistant temporal lobe epilepsy patients. J Neuroimmunol. 2019 Mar 15; 328: 68–72. https://doi.org/10.1016/j.jneuroim.2018.12.007. Epub 2018 Dec 21. PMID: 30597392.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kan A.A., de Jager W., de Wit M., et al. Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines. J Neuroinflammation. 2012 Aug 30; 9: 207. https://doi.org/10.1186/1742-2094-9-207. PMID: 22935090.</mixed-citation><mixed-citation xml:lang="en">Kan A.A., de Jager W., de Wit M., et al. Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines. J Neuroinflammation. 2012 Aug 30; 9: 207. https://doi.org/10.1186/1742-2094-9-207. PMID: 22935090.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Aalbers M.W., Rijkers K., Majoie H.J., et al. The influence of neuropathology on brain inflammation in human and experimental temporal lobe epilepsy. J Neuroimmunol. 2014 Jun 15; 271(1–2): 36–42. https://doi.org/10.1016/j.jneuroim.2014.03.016. Epub 2014 Mar 29. PMID: 24746448.</mixed-citation><mixed-citation xml:lang="en">Aalbers M.W., Rijkers K., Majoie H.J., et al. The influence of neuropathology on brain inflammation in human and experimental temporal lobe epilepsy. J Neuroimmunol. 2014 Jun 15; 271(1–2): 36–42. https://doi.org/10.1016/j.jneuroim.2014.03.016. Epub 2014 Mar 29. PMID: 24746448.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fiala M., Avagyan H., Merino J.J., et al. Chemotactic and mitogenic stimuli of neuronal apoptosis in patients with medically intractable temporal lobe epilepsy. Pathophysiology. 2013 Feb; 20(1): 59–69. https://doi.org/10.1016/j.pathophys.2012.02.003. Epub 2012 Mar 22. PMID: 22444245.</mixed-citation><mixed-citation xml:lang="en">Fiala M., Avagyan H., Merino J.J., et al. Chemotactic and mitogenic stimuli of neuronal apoptosis in patients with medically intractable temporal lobe epilepsy. Pathophysiology. 2013 Feb; 20(1): 59–69. https://doi.org/10.1016/j.pathophys.2012.02.003. Epub 2012 Mar 22. PMID: 22444245.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Omran A., Peng J., Zhang C., et al. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia. 2012 Jul; 53(7): 1215–1224. https://doi.org/10.1111/j.1528-1167.2012.03540.x. Epub 2012 Jun 18. PMID: 22708826.</mixed-citation><mixed-citation xml:lang="en">Omran A., Peng J., Zhang C., et al. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia. 2012 Jul; 53(7): 1215–1224. https://doi.org/10.1111/j.1528-1167.2012.03540.x. Epub 2012 Jun 18. PMID: 22708826.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nowak M., Bauer S., Haag A., et al. Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav Immun. 2011 Mar; 25(3): 423–428. https://doi.org/10.1016/j.bbi.2010.10.022. Epub 2010 Oct 25. PMID: 20977934.</mixed-citation><mixed-citation xml:lang="en">Nowak M., Bauer S., Haag A., et al. Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain Behav Immun. 2011 Mar; 25(3): 423–428. https://doi.org/10.1016/j.bbi.2010.10.022. Epub 2010 Oct 25. PMID: 20977934.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Uludag I.F., Bilgin S., Zorlu Y., et al. Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure. 2013 Jul; 22(6): 457–461. https://doi.org/10.1016/j.seizure.2013.03.004. Epub 2013 Apr 6. PMID: 23566695.</mixed-citation><mixed-citation xml:lang="en">Uludag I.F., Bilgin S., Zorlu Y., et al. Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure. 2013 Jul; 22(6): 457–461. https://doi.org/10.1016/j.seizure.2013.03.004. Epub 2013 Apr 6. PMID: 23566695.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Curia G., Longo D., Biagini G., et al. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008 Jul 30; 172(2): 143–157. https://doi.org/10.1016/j.jneumeth.2008.04.019. Epub 2008 Apr 26. PMID: 18550176.</mixed-citation><mixed-citation xml:lang="en">Curia G., Longo D., Biagini G., et al. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008 Jul 30; 172(2): 143–157. https://doi.org/10.1016/j.jneumeth.2008.04.019. Epub 2008 Apr 26. PMID: 18550176.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gao F., Gao Y., Zhang S.J., et al. Alteration of plasma cytokines in patients with active epilepsy. Acta Neurol Scand. 2017 Jun; 135(6): 663–669. https://doi.org/10.1111/ane.12665. Epub 2016 Sep 4. PMID: 27593211.</mixed-citation><mixed-citation xml:lang="en">Gao F., Gao Y., Zhang S.J., et al. Alteration of plasma cytokines in patients with active epilepsy. Acta Neurol Scand. 2017 Jun; 135(6): 663–669. https://doi.org/10.1111/ane.12665. Epub 2016 Sep 4. PMID: 27593211.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rahman M.T., Ghosh C., Hossain M., et al. IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuroinflammatory diseases. Biochem Biophys Res Commun. 2018 Dec 9; 507(1–4): 274–279. https://doi.org/10.1016/j.bbrc.2018.11.021. Epub 2018 Nov 16. PMID: 30449598.</mixed-citation><mixed-citation xml:lang="en">Rahman M.T., Ghosh C., Hossain M., et al. IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuroinflammatory diseases. Biochem Biophys Res Commun. 2018 Dec 9; 507(1–4): 274–279. https://doi.org/10.1016/j.bbrc.2018.11.021. Epub 2018 Nov 16. PMID: 30449598.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Beattie E.C., Stellwagen D., Morishita W., et al. Control of synaptic strength by glial TNFalpha. Science. 2002 Mar 22; 295(5563): 2282–2285. https://doi.org/10.1126/science.1067859. PMID: 11910117.</mixed-citation><mixed-citation xml:lang="en">Beattie E.C., Stellwagen D., Morishita W., et al. Control of synaptic strength by glial TNFalpha. Science. 2002 Mar 22; 295(5563): 2282–2285. https://doi.org/10.1126/science.1067859. PMID: 11910117.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci. 2005 Mar 23; 25(12): 3219–3228. https://doi.org/10.1523/JNEUROSCI.4486-04.2005. Erratum in: J Neurosci. 2005 Jun 1; 25(22): 1 p following 5454. PMID: 15788779.</mixed-citation><mixed-citation xml:lang="en">Stellwagen D., Beattie E.C., Seo J.Y., Malenka R.C. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci. 2005 Mar 23; 25(12): 3219–3228. https://doi.org/10.1523/JNEUROSCI.4486-04.2005. Erratum in: J Neurosci. 2005 Jun 1; 25(22): 1 p following 5454. PMID: 15788779.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bazhanova E.D., Kozlov A.A., Litovchenko A.V. Mechanisms of drug resistance in the pathogenesis of epilepsy: role of neuroinflammation. A literature review. Brain Sci. 2021 May 19; 11(5): 663. https://doi.org/10.3390/brainsci11050663. PMID: 34069567.</mixed-citation><mixed-citation xml:lang="en">Bazhanova E.D., Kozlov A.A., Litovchenko A.V. Mechanisms of drug resistance in the pathogenesis of epilepsy: role of neuroinflammation. A literature review. Brain Sci. 2021 May 19; 11(5): 663. https://doi.org/10.3390/brainsci11050663. PMID: 34069567.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Matkar P.N., Ariyagunarajah R., Leong-Poi H., Singh K.K. Friends turned foes: angiogenic growth factors beyond angiogenesis. Biomolecules. 2017 Oct 2; 7(4): 74. https://doi.org/10.3390/biom7040074. PMID: 28974056.</mixed-citation><mixed-citation xml:lang="en">Matkar P.N., Ariyagunarajah R., Leong-Poi H., Singh K.K. Friends turned foes: angiogenic growth factors beyond angiogenesis. Biomolecules. 2017 Oct 2; 7(4): 74. https://doi.org/10.3390/biom7040074. PMID: 28974056.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sladojevic N., Stamatovic S.M., Johnson A.M., et al. Claudin-1-dependent destabilization of the blood-brain barrier in chronic stroke. J Neurosci. 2019 Jan 23; 39(4): 743–757. https://doi.org/10.1523/JNEUROSCI.1432-18.2018. Epub 2018 Nov 30. PMID: 30504279.</mixed-citation><mixed-citation xml:lang="en">Sladojevic N., Stamatovic S.M., Johnson A.M., et al. Claudin-1-dependent destabilization of the blood-brain barrier in chronic stroke. J Neurosci. 2019 Jan 23; 39(4): 743–757. https://doi.org/10.1523/JNEUROSCI.1432-18.2018. Epub 2018 Nov 30. PMID: 30504279.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu H., Zhang Y., Zhong Y., et al. Inflammation-mediated angiogenesis in ischemic stroke. Front Cell Neurosci. 2021 Apr 21; 15: 652647. https://doi.org/10.3389/fncel.2021.652647. PMID: 33967696.</mixed-citation><mixed-citation xml:lang="en">25 Zhu H., Zhang Y., Zhong Y., et al. Inflammation-mediated angiogenesis in ischemic stroke. Front Cell Neurosci. 2021 Apr 21; 15: 652647. https://doi.org/10.3389/fncel.2021.652647. PMID: 33967696.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mühleder S., Fernández-Chacón M., Garcia-Gonzalez I., Benedito R. Endothelial sprouting, proliferation, or senescence: tipping the balance from physiology to pathology. Cell Mol Life Sci. 2021 Feb; 78(4): 1329–1354. https://doi.org/10.1007/s00018-020-03664-y. Epub 2020 Oct 19. PMID: 33078209.</mixed-citation><mixed-citation xml:lang="en">Mühleder S., Fernández-Chacón M., Garcia-Gonzalez I., Benedito R. Endothelial sprouting, proliferation, or senescence: tipping the balance from physiology to pathology. Cell Mol Life Sci. 2021 Feb; 78(4): 1329–1354. https://doi.org/10.1007/s00018-020-03664-y. Epub 2020 Oct 19. PMID: 33078209.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Son D.S., Parl A.K., Rice V.M., Khabele D. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther. 2007 Aug; 6(8): 1302–1312. https://doi.org/10.4161/cbt.6.8.4506. Epub 2007 May 26. PMID: 17712227.</mixed-citation><mixed-citation xml:lang="en">Son D.S., Parl A.K., Rice V.M., Khabele D. Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther. 2007 Aug; 6(8): 1302–1312. https://doi.org/10.4161/cbt.6.8.4506. Epub 2007 May 26. PMID: 17712227.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Øbro N.F., Grinfeld J., Belmonte M., et al. Longitudinal cytokine profiling identifies GRO-α and EGF as potential biomarkers of disease progression in essential thrombocythemia. Hemasphere. 2020 May 21; 4(3): e371. https://doi.org/10.1097/HS9.0000000000000371. PMID: 32647796.</mixed-citation><mixed-citation xml:lang="en">Øbro N.F., Grinfeld J., Belmonte M., et al. Longitudinal cytokine profiling identifies GRO-α and EGF as potential biomarkers of disease progression in essential thrombocythemia. Hemasphere. 2020 May 21; 4(3): e371. https://doi.org/10.1097/HS9.0000000000000371. PMID: 32647796.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Nii T., Yumoto H., Hirota K., Miyake Y. Anti-inflammatory effects of olanexidine gluconate on oral epithelial cells. BMC Oral Health. 2019 Nov 8; 19(1): 239. https://doi.org/10.1186/s12903-019-0932-0. PMID: 31703580.</mixed-citation><mixed-citation xml:lang="en">Nii T., Yumoto H., Hirota K., Miyake Y. Anti-inflammatory effects of olanexidine gluconate on oral epithelial cells. BMC Oral Health. 2019 Nov 8; 19(1): 239. https://doi.org/10.1186/s12903-019-0932-0. PMID: 31703580.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Griffith J.W., Sokol C.L., Luster A.D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014; 32: 659–702. https://doi.org/10.1146/annurev-immunol-032713-120145. PMID: 24655300.</mixed-citation><mixed-citation xml:lang="en">Griffith J.W., Sokol C.L., Luster A.D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014; 32: 659–702. https://doi.org/10.1146/annurev-immunol-032713-120145. PMID: 24655300.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Abbott N.J., Patabendige A.A., Dolman D.E., et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010 Jan; 37(1): 13–25. https://doi.org/10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5. PMID: 19664713.</mixed-citation><mixed-citation xml:lang="en">Abbott N.J., Patabendige A.A., Dolman D.E., et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010 Jan; 37(1): 13–25. https://doi.org/10.1016/j.nbd.2009.07.030. Epub 2009 Aug 5. PMID: 19664713.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Pérez-Pérez D., Frías-Soria C.L., Rocha L. Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources. Epilepsy Behav. 2021 Aug; 121(Pt B): 106430. https://doi.org/10.1016/j.yebeh.2019.07.031. Epub 2019 Aug 2. PMID: 31378558.</mixed-citation><mixed-citation xml:lang="en">Pérez-Pérez D., Frías-Soria C.L., Rocha L. Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources. Epilepsy Behav. 2021 Aug; 121(Pt B): 106430. https://doi.org/10.1016/j.yebeh.2019.07.031. Epub 2019 Aug 2. PMID: 31378558.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
